Literature DB >> 11597895

sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension.

S M Black1, L S Sanchez, E Mata-Greenwood, J M Bekker, R H Steinhorn, J R Fineman.   

Abstract

Utilizing aortopulmonary vascular graft placement, we established a lamb model of pulmonary hypertension that mimics congenital heart disease with increased pulmonary blood flow. We previously demonstrated that endothelial nitric oxide synthase (eNOS) is increased in lambs at age 4 wk. However, these lambs display a selective impairment of endothelium-dependent pulmonary vasodilation that is suggestive of a derangement downstream of NO release. Thus our objective was to characterize potential alterations in the expression and activity of soluble guanylate cyclase (sGC) and phosphodiesterase type 5 (PDE5) induced by increased pulmonary blood flow and pulmonary hypertension. Late-gestational fetal lambs (n = 10) underwent in utero placement of an aortopulmonary vascular graft (shunt). Western blotting analysis on lung tissue from 4-wk-old shunted lambs and age-matched controls showed that protein for both subunits of sGC was increased in shunted lamb lungs compared with age-matched controls. Similarly, cGMP levels were increased in shunted lamb lungs compared with age-matched controls. However, PDE5 expression and activity were also increased in shunted lambs. Thus although cGMP generation was increased, concomitant upregulation of PDE5 expression and activity may have (at least partially) limited and accounted for the impairment of endothelium-dependent pulmonary vasodilation in shunted lambs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11597895     DOI: 10.1152/ajplung.2001.281.5.L1051

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  22 in total

1.  Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Pulmonary hypertension complicating congenital heart disease.

Authors:  J Eduardo Rame
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

3.  Enhanced NO-dependent pulmonary vasodilation limits increased vasoconstrictor sensitivity in neonatal chronic hypoxia.

Authors:  Joshua R Sheak; Laura Weise-Cross; Ray J deKay; Benjimen R Walker; Nikki L Jernigan; Thomas C Resta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

4.  Transforming growth factor-β downregulates sGC subunit expression in pulmonary artery smooth muscle cells via MEK and ERK signaling.

Authors:  Lili Du; Jesse D Roberts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-09-27       Impact factor: 5.464

Review 5.  Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.

Authors:  Hiroshi Watanabe
Journal:  Eur Cardiol       Date:  2018-08

6.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

7.  Chronic inhibition of PPAR-γ signaling induces endothelial dysfunction in the juvenile lamb.

Authors:  Shruti Sharma; Jubilee Barton; Ruslan Rafikov; Saurabh Aggarwal; Hsuan-Chang Kuo; Peter E Oishi; Sanjeev A Datar; Jeffrey R Fineman; Stephen M Black
Journal:  Pulm Pharmacol Ther       Date:  2012-12-17       Impact factor: 3.410

Review 8.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

9.  Immunohistochemical localisation of PDE5 in rat lung during pre- and postnatal development.

Authors:  Angela Scipioni; Mauro Giorgi; Valeria Nuccetelli; Stefania Stefanini
Journal:  J Biomed Biotechnol       Date:  2009-08-20

10.  Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.

Authors:  Cong Wang; Ji-Feng Li; Lan Zhao; Jie Liu; Jun Wan; Yue Xiu Wang; Jun Wang; Chen Wang
Journal:  Respir Res       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.